🟢 GT Biopharma is trading 6.8% up in pre-market with no clear catalyst identified

GT Biopharma is trading at $7.51, up 6.8%, with no clear catalyst identified.

• The price compares with the October 16 close of $7.03.
• No new company-specific announcement dated October 19 was identified; the latest listed press release is dated September 15.
• Sector context was mixed: biotech ETF XBI was reported down pre-market while GT Biopharma was higher. No same-direction market explanation was established, and pre-market volume data was unavailable.